PF-06835919

DB19163InvestigationalSmall molecule

PF-06835919 is under investigation in clinical trial NCT05463575 (Ketohexokinase Inhibition in NAFLD).

Chemical structure of PF-06835919
Mechanism
Curator reviewed
Formula / weight
C16H19F3N4O2 · 356.349 g/mol (avg)
Also known as
(1α,5α,6α)-3-[2-[(2S)-2-Methyl-1-azetidinyl]-6-(trifluoromethyl)-4-pyrimidinyl]-3-azabicyclo[3.1.0]hexane-6-acetic acid · 2-((1S,5R)-3-(2-((2S)-2-METHYLAZETIDIN-1-YL)-6-(TRIFLUOROMETHYL)PYRIMIDIN-4-YL)-3-AZABICYCLO(3.1.0)HEXAN-6-YL)ACETIC ACID
Code names
PF-06835919

Resolves to

Compound
UNIIEC2P9H3A8SCAS2102501-84-6ChEMBLCHEMBL4549658
Structure
InChIKeyMDUYWDNWFXSMJJ-XWLWVQCSSA-NSMILES[H][C@@]12CN(C[C@]1([H])[C@H]2CC(O)=O)C1=CC(=NC(=N1)N1CC[C@@H]1C)C(F)(F)F
Targets
P50053KHK
Transporters
Q9Y6L6SLCO1B1Q9Y694SLC22A7

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
2TransportersSubstrate / inhibitor direction, not just membership
Listed above
8Clinical trialsPhase, status and sponsor resolved per trial
Sign in
13+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with PF-06835919, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In